FDA Launches New Pathway for Individualized Therapies for Rare Diseases

The Food and Drug Administration (FDA) has announced a new approval process designed to accelerate the development and availability of targeted, individualized therapies for rare and ultra-rare diseases. This new pathway, called the “plausible mechanism pathway,” aims to address the challenges of traditional clinical trials when dealing with conditions affecting small patient populations.

Addressing the Challenges of Rare Disease Treatment

Approximately 30 million Americans are affected by rare diseases¹. Historically, developing treatments for these conditions has been difficult due to the limited number of patients, making traditional randomized controlled trials infeasible. The FDA’s new framework seeks to overcome this hurdle by focusing on demonstrating a “plausible mechanism” of action and generating substantial evidence of effectiveness and safety.

The “Plausible Mechanism Pathway” Explained

Announced on February 23, 2026, by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. And FDA Commissioner Martin Makary, MD, MPH, the plausible mechanism pathway allows for approval based on a single, well-controlled clinical investigation supported by confirmatory evidence¹. This approach is particularly relevant for therapies like genome editing and RNA-based treatments.

A Real-World Example: CPS1 Deficiency

The development of this pathway was inspired by the successful treatment of an infant with carbamoyl-phosphate synthase 1 deficiency (CPS1), a rare genetic disorder. Researchers at the Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania developed a personalized gene editing therapy for the infant. Kiran Musunuru, MD, PhD, MPH, a cardiologist, geneticist and gene editor at the University of Pennsylvania, explained that the therapy utilizes a “GPS-like” component that can be reprogrammed to target different genes². This allows for the creation of individualized treatments for various liver-centered diseases by simply modifying the “GPS” to correct each patient’s specific genetic misspelling.

Key Elements of the Proposed Pathway

The FDA’s proposed pathway includes five key elements¹:

• Identifying molecular or cellular abnormalities
• Targeting the underlying alteration
• Use of natural history data
• Evidence of successful application of the technology
• Demonstration of clinical benefit

The protocol also includes stipulations for FDA approval and post-marketing analyses.

Bridging the Gap to Commercial Availability

Rebecca Ahrens-Nicklas, MD, PhD, director of the CHOP Gene Therapy for Inherited Metabolic Disorders Program, highlighted the challenges of translating promising science into accessible treatments. “The biggest hurdle is moving from a first-in-human trial to regulatory approval,” she stated. “Getting across that gap is what allows treatments to become commercially available, reimbursed and scaled, so all patients who need them can access them, not just those in a single, small study.”

Looking Ahead

The FDA’s new framework represents a significant step forward in addressing the unmet needs of patients with rare diseases. By streamlining the approval process for individualized therapies, the agency hopes to accelerate the development and delivery of life-changing treatments to those who need them most. Researchers and developers are urged to maintain meticulous data collection, as “every single piece of data from every patient is priceless”².

References:

1. “FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases.” HHS. Published Feb. 23, 2026.
2. Q&A: Accelerating time to treatment in ischemic stroke requires better logistics – Healio